Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Name||inflammatory breast carcinoma|
|Definition||A breast adenocarcinoma that is characterized by the clinical appearance of inflammation, with edema and redness of the breast due to pathologic plugging of the dermal lymphatics of the breast with tumor emboli.|
|Path||disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer breast carcinoma breast adenocarcinoma inflammatory breast carcinoma|
|Molecular Profile||Therapy||Indication/Tumor Type||Response Type||Profile Response Detail|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02411656||Phase II||Pembrolizumab||Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy||Active, not recruiting||USA||0|
|NCT02971748||Phase II||Pembrolizumab||Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy||Active, not recruiting||USA||0|
|NCT03202316||Phase II||Atezolizumab + Cobimetinib + Eribulin||Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer||Recruiting||USA||0|
|NCT03598257||Phase II||Olaparib||Radiation Therapy With or Without Olaparib in Treating Participants With Inflammatory Breast Cancer||Recruiting||USA | CAN||1|
|NCT03742986||Phase II||Cyclophosphamide + Doxorubicin Nivolumab + Paclitaxel Docetaxel + Nivolumab + Pertuzumab + Trastuzumab||Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)||Active, not recruiting||USA||0|
|NCT05093387||Phase I||Carboplatin + Pembrolizumab + SGT-53||SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer||Withdrawn||USA||0|
|NCT05243641||Phase Ib/II||Capmatinib + Neratinib||Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER2 and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test||Recruiting||USA||0|